

# Phase I study of GFH018, a small molecular TGF-βRI inhibitor, in patients with advanced solid tumors

Y. Guo<sup>1</sup>, W. Zishu<sup>2</sup>, H. Zhou<sup>2</sup>, H. Pan<sup>3</sup>, W. han<sup>3</sup>, Y. Deng<sup>4</sup>, Y. zhang<sup>5</sup>, H. Ren<sup>6</sup>, H. Zhang<sup>7</sup>, S. Wang<sup>7</sup>, Y. Zhang<sup>7</sup>, J. Li<sup>1</sup> <sup>1</sup>Department of Medical Oncology, the Affiliated East Hospital Of Tongji University, Shanghai, China, <sup>2</sup>Department of Medical Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, China, <sup>3</sup>Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medical Oncology, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, <sup>5</sup>Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China, <sup>6</sup>Department of Pharmacology, GenFleet Therapeutics Inc., Shanghai, China

#### Introduction

- TGF-β is a multifunctional polypeptide cytokine and the pathway is a classic membrane-to-nucleus signaling process involving direct receptor-mediated activation of SMAD transcription factors<sup>1</sup>.
- TGF-β pathway activation promotes tumor metastasis and progression, mediates epithelial-mesenchymal transmission suppressing immunosurveillance in advanced tumors<sup>2, 3</sup>. High expression of TGF-β always correlates with poor disease prognosis<sup>4, 5</sup>.
- Inhibition of TGF-β signaling pathway can inhibit tumor growth and progression through multiple ways, including inhibiting metastasis, enhancing anti-tumor immune responses within the tumor microenvironment, and inhibiting intra-tumor angiogenesis<sup>6</sup>.
- Biological rationales have been provided for combining PD-1/L1 with TGF-β inhibitors. Inhibiting TGF-β pathway impacts regulatory T cell production and can potentially augment the effect of PD-1/L1 inhibitors leading to improved response<sup>6</sup>.


#### Investigational treatment

- GFH018, a novel small molecule that inhibits TGF-βRI kinase, blocks TGF- $\beta$  signaling transduction thus inhibits tumor progression.
- GFH018 can inhibit kinase activity of TGF-βRI and inhibit Smad2/3 protein phosphorylation and gene expression induced by TGF-β-Smad signaling pathway in vitro.
- GFH018 showed significant anti-tumor activity in single agent as well as a synergistic effect with PD-1/L1 immune checkpoint inhibitors in low dose in vivo.

#### Methods

NCT05051241 is an ongoing, phase I, open-label, multicenter study.

- Comprising of a modified 3 + 3 dose escalation part followed by an expansion part. GFH018 doses of 5mg up to 85 mg twice daily were tested.
- Eligible patients with advanced solid tumors failed to standard therapies were administrated with GFH018 BID orally, 14-day on/14-day off.
- AEs were graded per NCI-CTCAE v5.0. PK analysis was performed using a non-compartmental method. Tumor response was evaluated per RECIST 1.1.



#### Figure 1. Study Design

- Adverse events of special interest (AESI) was defined as below:
- Increased cardiac biomarkers with clinical significance, brain natriuretic including N-terminal prohormone peptide (NT-proBNP) and troponin.
- Abnormal echocardiography with clinical significance.

### Key inclusion criteria

- Aged 18-75 years old.
- Previously treated, histologically or cytologically confirmed advanced solid tumors.
- At least one evaluable lesion per RECIST 1.1.
- ECOG performance status 0-1.
- Life expectancy  $\geq$  12w.

### Key exclusion criteria

- With unstable CNS metastasis.
- With clinically significant cardiac diseases.
- Active infection.
- History of autoimmune disease.
- History of prior anti-tumor therapy within the protocolspecified timeframe.

#### Results

#### **Baseline and disease characteristics**

- As of Jan 25, 2022, 39 patients (5 mg [n=4]; 10 mg [n=3]; 20mg [n=4]; 30 mg [n=7]; 40, 50 mg [n=4 each]; 65 mg [n=6] and 85 mg [n=7]) were sequentially enrolled in the dose escalation part.
- 79.5% (n=31) of enrolled patients received  $\geq$  3 prior antitumor therapies.
- 56.4% (n=22) of patients received anti-PD-1 antitumor therapy previously.

#### Table 1. Baseline and disease characteristics

	Total (N=39)
Age (years), Median (range)	53.0 (27-68)
Sex, n (%)	
Male	17 (43.6%)
Weight (kg) , Median (range)	59.3 (34.5-83.1)
ECOG performance status, n (%)	
0/1	3 (7.7%)/36 (92.3%)
Lines of prior anti-tumor therapies, n (%)	
1	3 (7.7%)
2	5 (12.8%)
≥ 3	31 (79.5%)
Have ever received anti-PD-1 therapy, n (%)	
Yes	22 (56.4%)

#### **Safety**

- No dose limiting toxicity (DLT) was observed and the maximal tolerance dose (MTD) was not reached.
- No patients discontinued due to AEs.
- 35 patients (89.7%) had at least one treatment related AE and 2 (5.1%) experienced  $\geq$  G3 treatment related AE.

- Bleeding events

#### Table 2. TEAEs or TRAEs occur in $\geq$ 5 patients **Treatment-Emergent AEs Treatment-Related AEs** ≥ G3 ≥ G3 Any grades Any grades n (%) n (%) n (%) n (%) 17 (44.7%) 8 (20.5%) 1 (2.6%) 2 (5.1%) Anemia\* 17 (44.7%) 2 (5.1%) 5 (12.8%) Lymphocyte count 8 (20.5%) 2 (5.1%) 4 (10.3%) 1 (2.6%) 7 (17.9%) 6 (15.4%) 0 7 (17.9%) 4 (10.3%) LDH increased 7 (17.9%) 4 (10.3%) 0 Sinus tachycardia 7 (17.9%) 3 (7.7%) 6 (15.4%) 1 (2.6%) 1 (2.6%) DBIL increased 0 ALT increased 6 (15.4%) 5 (12.8%) GGT increased 6 (15.4%) 3 (7.7%) 0 Asthenia 6 (15.4%) 1 (2.6%) 6 (15.4%) 1 (2.6%) 5 (12.8%) 2 (5.1%)


#### Proteinuria<sup>#</sup>

- decreased
- **AST** increased
- **ALK** increased

#### Constipation

Abdominal pain both anemia and hemoglobin decreased.

### Figure 2. Efficacy data of GFH018 monotherapy (Swimmer plot)



**Abbreviations: SD**, stable disease. **PD**, progressive disease. ACC, adenoid cystic carcinoma. BC, breast cancer. BTC, biliary tract cancer. CRC, colorectal cancer. DA, duodenal adenocarcinoma. **EC**, endometrial carcinoma. **GEJC**, gastroesophageal junction carcinoma. MCLN, metastatic carcinoma of lymph nodes. MPM, malignant pleural mesothelioma. NSCLC, non small cell lung cancer. NPC, nasopharyngeal carcinoma. OC, ovarian cancer. PA, pancreatic adenocarcinoma. PP, pelvic paraganglioma. RPC, renal pelvis carcinoma. SCLC, small cell lung cancer. THYM, thymic carcinoma.

The presenter states no conflict-of-interest on the poster. **Contact:** Y. Guo<sup>1</sup>, pattrickguo@gmail.com


• The most common treatment-related AEs (all Grade/≥G3) were proteinuria (20.5%/2.6%), AST increased (15.4%/0), ALT increased (12.8%/0), anemia (12.8%/0), lymphocyte count decreased (10.3%/2.6%), ALP increased (10.3%/0), and LDH increased (10.3%/0). Cardiovascular toxicity

• No  $\geq$  G2 AESIs were reported. Only G1 Troponin T from 10mg BID cohort or G1 NT-proBNP from 30mg BID cohort increased was reported respectively in two patients without symptoms or signs.

• No bleeding events were reported.

#The term proteinuria includes both proteinuria and protein urine present. \*The term anemia includes

Abbreviations: TEAE, treatment-emergent adverse event. TRAE, treatment-related adverse event.



**PK**, pharmacokinetics.

#### Efficacy

- patients.
- as of the cut-off date.

## **Pharmacokinetics (PK)**

#### Conclusions

- risk.

#### References

- 1750.

#### Acknowledgments

The authors would like to thank the participating patients, their families, the investigators and co-investigators, and the study teams at each of the participating centers.

• Five patients achieved stable disease (SD) out of 24 evaluable

• One patient with thymic carcinoma receiving GFH018 at 50 mg achieved a durable SD with tumor shrinkage (maximum lesion decreased by 18.4%) and has stayed on treatment for 185 days

• PK of GFH018 was linear and dose-independent with geometric mean half-life in the range of 3.11 h- 8.30 h.

• Accumulation in PK exposure was limited post multiple dosing.

 GFH018 in the current dosing regimen presented a favorable safety profile without cardiovascular toxicity and hemorrhage

Preliminary efficacy of GFH018 as monotherapy was observed in treating among patients with advanced solid tumors. Two clinical studies of GFH018 in combination with Toripalimab (NCT04914286) and with Toripalimab+ concurrent chemoradiotherapy (NCT05386888) are ongoing.

1. Batlle E, et al. Immunity. 2019 Apr 16;50(4):924-940. 2. Hao Y, et al. Int J Mol Sci. 2019;20(11):2767. 3. An Y, et al. World J Gastroenterol 2018; 25: 2733-2740 4. Peng L, et al. Oncotarget 2017; 8: 34387-34397 5. Calon A, et al. Nat Genet 2015; 47:320-329. 6. Haque S, ey al. Hum Vaccin Immunother. 2017;13(8):1741-